Omberacetam

Omberacetam (GVS-111) is a medication promoted and prescribed in Russia and neighbouring countries as a nootropic.

Product Specifications

CAS Number

[157115-85-0]

Product Name Alternative

GVS-111; SGS-111

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/noopept.html

Purity

99.86

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(OCC)CNC([C@H]1N(C(CC2=CC=CC=C2)=O)CCC1)=O

Molecular Formula

C17H22N2O4

Molecular Weight

318.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Firstova IuIu, et al. Studying specific effects of nootropic drugs on glutamate receptors in the rat brain. Eksp Klin Farmakol. 2011;74 (1) :6-10.|[2]Pelsman A, et al. GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. Int J Dev Neurosci. 2003 May;21 (3) :117-24.|[3]Ostrovskaya RU, et al. Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model. Behav Pharmacol. 1999 Sep;10 (5) :549-53.|[4]Gudasheva TA, et al. The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. Eur J Drug Metab Pharmacokinet. 1997 Jul-Sep;22 (3) :245-52.|[5]Kovalenko LP, et al. Anti-inflammatory properties of noopept (dipeptide nootropic agent GVS-111) . Eksp Klin Farmakol. 2002 Mar-Apr;65 (2) :53-5.|[6]Kovalenko LP, et al. Preclinical study of noopept toxicity. Eksp Klin Farmakol. 2002 Jan-Feb;65 (1) :62-4.